-
Innovation Ranking
NewInnovation Ranking – Mitsui E&S Holdings Co Ltd
Mitsui E&S Holdings Co Ltd (Mitsui E&S) is a shipbuilding and engineering product manufacturing company. It has diversified business operations comprising, the construction of social infrastructure, advanced machinery systems, IT-related activities, ships and oceans, plant construction, logistics systems, and energy system. Mitsui E&S serves industrial, commercial, public, and private infrastructure projects. The company’s technology development includes Close-up technology which provides natural gas hydrate system, use of biomass in the production of ethanol, and underwater equipment. The company operates along with...
-
Product Insights
NewNet Present Value Model: Shionogi & Co Ltd’s S-309309
Empower your strategies with our Net Present Value Model: Shionogi & Co Ltd's S-309309 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Seelos Therapeutics, Inc.’s Ketamine Hydrochloride
Empower your strategies with our Net Present Value Model: Seelos Therapeutics, Inc.'s Ketamine Hydrochloride report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Shionogi & Co Ltd’s S-588410
Empower your strategies with our Net Present Value Model: Shionogi & Co Ltd's S-588410 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – S-1226 in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - S-1226 in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. S-1226 in Asthma Drug Details: S-1226 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Peltopepimut-s in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Peltopepimut-s in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Peltopepimut-s in Oropharyngeal Cancer Drug Details: Peltopepimut-s (ISA-101) is under development for...
-
Product Insights
NewNet Present Value Model: SELLAS Life Sciences Group Inc’s Galinpepimut-S
Empower your strategies with our Net Present Value Model: SELLAS Life Sciences Group Inc's Galinpepimut-S report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – S-65487 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - S-65487 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. S-65487 in Follicular Lymphoma Drug Details: S-65487 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – S-120083 in Osteoarthritis Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - S-120083 in Osteoarthritis Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. S-120083 in Osteoarthritis Pain Drug Details: S-120083 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – S-120083 in Inflammatory Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - S-120083 in Inflammatory Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. S-120083 in Inflammatory Pain Drug Details: S-120083 is under development for the...